Clough Global Dividend and Income Fund

STATEMENT OF INVESTMENTS

January 31, 2022 (Unaudited)

	Shares		Value
COMMON STOCKS 82.56%
Consumer Discretionary 5.36%
DR Horton, Inc.(a)(b)		37,500	$	3,345,750
Lennar Corp. - Class A(a)(b)		28,740		2,762,201
				6,107,951
Financials 26.34%(c)
Barings BDC, Inc.(a)		157,400		1,706,216
Blackstone Secured Lending Fund(a)(b)		37,400		1,081,982
Citigroup, Inc.(a)		30,300		1,973,136
Equitable Holdings, Inc.(a)(b)		100,800		3,390,912
Fidelity National Financial, Inc.(a)(b)		46,600		2,346,310
First American Financial Corp.(a)(b)		85,990		6,407,115
PennyMac Financial Services, Inc.(a)		63,730		3,995,871
Redwood Trust, Inc.(a)(b)		350,300		4,319,199
Starwood Property Trust, Inc.(a)(b)		114,900		2,843,775
Walker & Dunlop, Inc.(a)(b)		14,870		1,968,937
				30,033,453
Health Care 9.95%
Eli Lilly & Co.(a)(b)		12,013		2,947,870
Johnson & Johnson(a)(b)		11,340		1,953,769
McKesson Corp.(a)		904		232,075
Merck & Co., Inc.(a)(b)		27,700		2,256,996
Thermo Fisher Scientific, Inc.(a)		1,770		1,028,901
UnitedHealth Group, Inc.(a)		4,190		1,980,068
Zoetis, Inc.(a)(b)		4,750		949,002
				11,348,681
Industrials 9.85%
Airbus SE(d)		16,265		2,048,748
Raytheon Technologies Corp.(a)(b)		72,600		6,547,794
TransDigm Group, Inc.(a)(b)(d)		4,287		2,641,607
				11,238,149
Information Technology 30.19%(c)
Infineon Technologies AG		72,482		2,958,740
Lam Research Corp.(a)		2,830		1,669,474
MediaTek, Inc.		57,600		2,226,217
Micron Technology, Inc.(a)(b)		82,000		6,746,140
Microsoft Corp.(a)(b)		22,000		6,841,560
NVIDIA Corp.		8,040		1,968,674
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(a)(b)		48,300		5,923,029
Visa, Inc. - Class A(a)(b)		26,960		6,097,543
				34,431,377

	Shares		Value
Materials 0.87%
China Resources Cement Holdings, Ltd.		1,158,000	$	995,069
TOTAL COMMON STOCKS
(Cost $83,570,257)				94,154,680
PREFERRED STOCKS 1.00%
Gabelli Equity Trust, Inc.
Series K, Perpetual Maturity 5.000%(e)		21,200		548,338
Trinity Capital, Inc., 01/16/2025 7.000%(a)		22,400		585,200
TOTAL PREFERRED STOCKS
(Cost $1,090,000)				1,133,538

Underlying Security/Expiration Date/ Exercise Price/Notional Amount	Contracts	Value
PURCHASED OPTIONS 0.62%
Put Options Purchased 0.62%
S&P 500® Index
03/18/22, $4,250, $48,316,385	107	704,595
Total Put Options Purchased
(Cost $1,385,545)		704,595

Description/Maturity Date/Rate		Principal Amount	Value
CORPORATE BONDS 12.34%
Consumer Discretionary
Carvana Co.
10/01/2025, 5.625%(f)(g)	$	500,000	475,092
10/01/2028, 5.875%(a)(b)(f)(g)		1,000,000	941,245
Melco Resorts Finance, Ltd.
07/21/2028, 5.750%(f)(g)		250,000	240,354
PulteGroup, Inc.
01/15/2027, 5.000%		500,000	555,795
			2,212,486
Financials
AerCap Ireland Capital DAC / AerCap Global Aviation Trust
10/29/2023, 1.150%		1,000,000	987,656
Golub Capital BDC, Inc.
08/24/2026, 2.500%(a)		1,035,000	998,095
Main Street Capital Corp.
07/14/2026, 3.000%(a)		1,600,000	1,568,869
Nationstar Mortgage Holdings, Inc.
12/15/2030, 5.125%(a)(f)(g)		1,500,000	1,409,385
11/15/2031, 5.750%(f)(g)		500,000	484,120
Owl Rock Capital Corp.
01/15/2027, 2.625%(a)		1,260,000	1,208,148
Owl Rock Technology Finance Corp.
06/30/2025, 6.750%(a)(f)(g)		1,000,000	1,104,805
12/15/2025, 4.750%(a)(f)(g)		1,000,000	1,043,827
SLR Investment Corp.
01/20/2023, 4.500%		500,000	504,144

Description/Maturity Date/Rate	Principal Amount		Value
CORPORATE BONDS (continued)
Trinity Capital, Inc.
08/24/2026, 4.375%	$	500,000	$	496,394
				9,805,443
Industrials
Hexcel Corp.
02/15/2027, 4.200%(a)		1,000,000		1,042,171
Real Estate
Equinix, Inc.
11/18/2029, 3.200%(a)(b)		1,000,000		1,012,581
TOTAL CORPORATE BONDS
(Cost $14,589,897)				14,072,681
CONVERTIBLE CORPORATE BONDS 2.88%
Financials
Starwood Property Trust, Inc.
04/01/2023, 4.375%(a)(b)		977,000		1,014,774
Health Care
Gossamer Bio, Inc.
06/01/2027, 5.000%(a)(b)		1,070,000		929,830
Teladoc Health, Inc.
06/01/2027, 1.250%(a)(b)		1,500,000		1,341,000
				2,270,830
TOTAL CONVERTIBLE CORPORATE BONDS
(Cost $3,479,873)				3,285,604
ASSET-BACKED SECURITIES 0.04%
United States Small Business Administration
Series 2008-20L, Class 1, 12/01/2028, 6.220%(a)		37,993		41,326
TOTAL ASSET-BACKED SECURITIES
(Cost $37,993)				41,326
GOVERNMENT & AGENCY OBLIGATIONS 51.19%
U.S. Treasury Notes
08/31/2022, 1.625%		1,000,000		1,006,201
11/15/2022, 1.625%(a)		4,000,000		4,029,688
01/31/2023, 0.125%(a)		5,000,000		4,965,871
09/30/2023, 0.250%(a)		2,000,000		1,973,125
12/31/2023, 0.750%		16,000,000		15,876,250
01/31/2024, 0.875%		5,000,000		4,970,117
06/30/2024, 1.750%(a)		2,000,000		2,022,891
02/28/2025, 1.125%(a)		3,900,000		3,868,160
11/30/2026, 1.250%		3,000,000		2,951,016
02/28/2027, 1.125%(a)		6,600,000		6,442,219
11/15/2027, 2.250%(a)		6,200,000		6,392,539

Description/Maturity Date/Rate	Principal Amount		Value
GOVERNMENT & AGENCY OBLIGATIONS (continued)
06/30/2028, 1.250%(a)	4,000,000	$	3,883,125
TOTAL GOVERNMENT & AGENCY OBLIGATIONS
(Cost $59,626,211)			58,381,202

	Shares		Value
SHORT-TERM INVESTMENTS 7.29%
Money Market Funds  7.29%
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.010% 7-day yield)		8,314,571		8,314,571
TOTAL SHORT-TERM INVESTMENTS
(Cost $8,314,571)				8,314,571
Total Investments - 157.92%
(Cost $172,094,347)				180,088,197
Liabilities in Excess of Other Assets - (57.92%)(h)				(66,048,421	)
NET ASSETS - 100.00%			$	114,039,776

SCHEDULE OF SECURITIES SOLD SHORT	Shares			Value
COMMON STOCKS (9.97%)
Consumer Discretionary (2.48%)
JD.com, Inc. - Class A(d)	(1,666	)		(59,743	)
QuantumScape Corp.(d)	(48,700	)		(812,803	)
Rivian Automotive, Inc. - Class A(d)	(29,800	)		(1,959,052	)
				(2,831,598	)
Industrials (0.93%)
Snap-on, Inc.	(5,080	)		(1,057,910	)
Information Technology (6.56%)
Atlassian Corp. PLC - Class A(d)	(3,200	)		(1,037,888	)
International Business Machines Corp.(d)	(23,900	)		(3,192,323	)
MongoDB, Inc.(d)	(1,160	)		(469,928	)
Monolithic Power Systems, Inc.(d)	(2,280	)		(918,680	)
Wolfspeed, Inc.(d)	(9,400	)		(885,856	)
Zscaler, Inc.(d)	(3,800	)		(977,018	)
				(7,481,693	)
TOTAL COMMON STOCKS
(Proceeds $11,483,643)				(11,371,201	)
EXCHANGE TRADED FUNDS (1.95%)
SPDR S&P® Biotech ETF	(23,800	)		(2,223,634	)
TOTAL EXCHANGE TRADED FUNDS
(Proceeds $2,274,846)				(2,223,634	)
TOTAL SECURITIES SOLD SHORT
(Proceeds $13,758,489)			$	(13,594,835	)

Investment Abbreviations:

FEDEF - Federal Funds Effective Rate

FEDEF Rates:

1D FEDEF - 1 Day FEDEF as of January 31, 2022 was 0.08% 

^(a) Pledged security; a portion or all of the security is pledged as collateral for securities sold short, total return swap contracts, or borrowings. As of January 31, 2022, the aggregate value of those securities was $122,720,969, representing 107.61% of net assets. (See Note 1)

^(b) Loaned security; a portion or all of the security is on loan as of January 31, 2022.

^(c) When sector categorization is categorized by industry, no industry exceeds the 25% maximum specified in the Statement of Additional Information.

^(d) Non-income producing security.

^(e) This security has no contractual maturity date, is not redeemable and contractually pays an indefinite stream of interest.

^(f) Restricted Security (See Note 1).

^(g) Security is exempt from registration of the Securities Act of 1933.  These securities may be resold in transactions exempt from registration under Rule 144A, normally to qualified institutional buyers. As of January 31, 2022, these securities had an aggregate value of $5,698,828 or 5.00% of net assets.

^(h) Includes cash which is being held as collateral for futures contracts, total return swap contracts and securities sold short.

TOTAL RETURN SWAP CONTRACTS

Counter Party	Reference Entity/Obligation	Notional Amount		Floating Rate Paid by the Fund*	Floating Rate Index	Termination  Date	Value		Net Unrealized Appreciation
Morgan Stanley	Goertek, Inc.	$	2,116,433	1D FEDEF -250 bps	1D FEDEF	11/21/2023	$	1,852,378	$	264,055
Morgan Stanley	BYD Co., Ltd.		4,476,152	1D FEDEF -250 bps	1D FEDEF	11/21/2023		3,566,604		909,548
Morgan Stanley	Contemporary Amperex Technology Co., Ltd.		2,798,521	1D FEDEF - 250 bps	1D FEDEF	11/21/2023		2,457,782		340,739
		$	9,391,106				$	7,876,764	$	1,514,342

Counter Party	Reference Entity/Obligation	Notional Amount		Floating Rate Paid by the Fund*	Floating Rate Index	Termination  Date	Value		Net Unrealized Depreciation
Morgan Stanley	Luxshare Precision Industry Co., Ltd.	$	1,950,337	1D FEDEF - 250 bps	1D FEDEF	11/21/2023	$	1,965,990	$	(15,653	)
TOTAL		$	11,341,443				$	9,842,753	$	1,498,690

CALL OPTIONS WRITTEN

		Expiration	Strike					Notional
Underlying Security	Counterparty	Date	Price		Contracts			Amount		Value
S&P 500® Index	Morgan Stanley	03/18/2022	$	4,000		(107	)	$	48,316,385	$	(353,100	)
								$	48,316,385	$	(353,100	)

Clough Global Equity Fund

STATEMENT OF INVESTMENTS

January 31, 2022 (Unaudited)

	Shares		Value
COMMON STOCKS 114.37%
Communication Services 3.45%
Alphabet, Inc. - Class C(a)(b)(c)		875	$	2,374,724
Netflix, Inc.(a)		2,300		982,422
ViacomCBS, Inc. - Class B(b)(c)		121,400		4,060,830
				7,417,976
Consumer Discretionary 16.41%
Amazon.com, Inc.(a)(b)(c)		4,644		13,892,387
Carnival Corp.(a)(b)(c)		135,900		2,692,179
DR Horton, Inc.(b)(c)		69,000		6,156,180
Lennar Corp. - Class A(b)(c)		45,780		4,399,916
Royal Caribbean Cruises Ltd.(a)(b)(c)		39,320		3,059,489
Tesla, Inc.(a)(b)(c)		5,396		5,054,541
				35,254,692
Financials 21.63%
Barings BDC, Inc.(b)		361,146		3,914,823
Citigroup, Inc.(b)		63,100		4,109,072
Equitable Holdings, Inc.(b)(c)		226,900		7,632,916
Fidelity National Financial, Inc.(b)(c)		99,150		4,992,202
First American Financial Corp.(b)(c)		158,590		11,816,541
PennyMac Financial Services, Inc.(b)		130,180		8,162,286
Starwood Property Trust, Inc.(b)(c)		235,300		5,823,675
				46,451,515
Health Care 35.11%(d)
Acadia Healthcare Co., Inc.(a)(b)(c)		38,800		2,042,820
Amphivena Therapeutics, Inc. - Series C(a)(e)(f)(g)(h)(i)		334,425		1,391,753
Apellis Pharmaceuticals, Inc.(a)(b)(c)		29,697		1,195,898
Arcellx, Inc. - Series B(a)(e)(f)(g)(h)(i)		421,845		881,234
Arcellx, Inc. - Series C(a)(e)(f)(g)(h)(i)		78,692		164,388
Arvinas, Inc.(a)(b)(c)		66,700		4,768,383
C4 Therapeutics, Inc.(a)(b)		84,400		2,061,892
Centrexion Therapeutics Corp.(a)(e)(g)(h)(i)		4,336		53,732
Centrexion Therapeutics Corp. - Series D Preferred Shares(a)(e)(f)(g)(h)(i)		66,719		826,782
Checkmate Pharmaceuticals, Inc.(a)(b)		330,872		807,328
Community Health Systems, Inc.(a)(b)(c)		283,612		3,599,036
CRISPR Therapeutics AG(a)(b)		25,050		1,596,938
Doximity, Inc. - Class A(a)(b)		40,990		1,867,914
Envista Holdings Corp.(a)(b)		88,900		3,844,036
HCA Healthcare, Inc.(b)		9,110		2,186,855
Hologic, Inc.(a)(b)(c)		52,840		3,711,482
iRhythm Technologies, Inc.(a)(b)		7,385		921,870
Jazz Pharmaceuticals PLC(a)(b)(c)		30,710		4,265,926
Johnson & Johnson(b)(c)		24,560		4,231,442
Kymera Therapeutics, Inc.(a)(b)		53,955		2,266,110
Legend Biotech Corp. - ADR(a)(b)(c)		60,900		2,596,776
McKesson Corp.(b)(c)		1,956		502,144

	Shares		Value
Health Care (continued)
Merck & Co., Inc.(b)(c)	60,500	$	4,929,540
Mirati Therapeutics, Inc.(a)(b)(c)	12,520		1,493,636
Nurix Therapeutics, Inc.(a)(b)	116,300		2,165,506
Surgery Partners, Inc.(a)(b)	85,900		3,665,353
Teladoc Health, Inc.(a)(b)	22,340		1,713,701
Tenet Healthcare Corp.(a)(b)	28,700		2,127,244
Thermo Fisher Scientific, Inc.(b)	3,430		1,993,859
UnitedHealth Group, Inc.(b)	8,510		4,021,571
Veracyte, Inc.(a)(b)(c)	73,010		2,220,234
Vertex Pharmaceuticals, Inc.(a)(b)(c)	15,085		3,666,409
Zoetis, Inc.(b)(c)	8,190		1,636,280
			75,418,072
Industrials 8.08%
Airbus SE(a)	40,545		5,107,071
The Boeing Co.(a)(b)	18,900		3,784,536
Hertz Global Holdings, Inc.(a)(b)	43,000		828,180
Raytheon Technologies Corp.(b)	42,200		3,806,018
TransDigm Group, Inc.(a)(b)(c)	6,217		3,830,853
			17,356,658
Information Technology 29.69%(d)
GoDaddy, Inc. - Class A(a)(b)	47,700		3,611,367
Infineon Technologies AG	158,758		6,480,555
Lam Research Corp.(b)(c)	5,810		3,427,435
MediaTek, Inc.	125,300		4,842,795
Micron Technology, Inc.(b)(c)	172,400		14,183,348
Microsoft Corp.(b)(c)	46,630		14,500,998
NVIDIA Corp.	16,120		3,947,143
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(b)(c)	104,100		12,765,783
			63,759,424
TOTAL COMMON STOCKS
(Cost $238,701,385)			245,658,337
WARRANTS 0.98%(a)
Hertz Global Holdings, Inc., Strike Price $13.80, Expires 6/30/2051	171,590		2,108,841
TOTAL WARRANTS
(Cost $2,854,844)			2,108,841

Underlying Security/Expiration Date/ Exercise Price/Notional Amount	Contracts	Value
PURCHASED OPTIONS 0.66%
Put Options Purchased 0.66%
S&P 500® Index
03/18/22, $4,250, $97,084,325	215	1,415,775
Total Put Options Purchased
(Cost $2,784,040)		1,415,775

Description/Maturity Date/Rate		Principal Amount		Value
CONVERTIBLE CORPORATE BONDS 0.05%
Health Care
Amphivena Convertible Note PP
12/31/2049 (e)(f)(g)(h)(i)	$	108,750	$	108,750
TOTAL CONVERTIBLE CORPORATE BONDS
(Cost $108,750)				108,750
GOVERNMENT & AGENCY OBLIGATIONS 38.29%
U.S. Treasury Notes
08/31/2022, 1.625%(b)		4,000,000		4,024,803
11/15/2022, 1.625%(b)		5,000,000		5,037,110
01/31/2023, 0.125%(b)		15,000,000		14,897,615
09/30/2023, 0.250%(b)		10,000,000		9,865,625
12/31/2023, 0.750%(b)		29,000,000		28,775,703
01/31/2024, 0.875%		7,000,000		6,958,164
11/30/2026, 1.250%(b)		5,000,000		4,918,359
06/30/2028, 1.250%(b)		8,000,000		7,766,250
TOTAL GOVERNMENT & AGENCY OBLIGATIONS
(Cost $82,931,284)				82,243,629

	Shares		Value
SHORT-TERM INVESTMENTS 12.41%
Money Market Funds  12.41%
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.010% 7-day yield)	26,649,816		26,649,816
TOTAL SHORT-TERM INVESTMENTS
(Cost $26,649,816)			26,649,816
Total Investments - 166.76%
(Cost $354,030,119)			358,185,148
Liabilities in Excess of Other Assets - (66.76%)(j)			(143,395,898	)
NET ASSETS - 100.00%		$	214,789,250

SCHEDULE OF SECURITIES SOLD SHORT	Shares		Value
COMMON STOCKS (12.60%)
Consumer Discretionary (2.68%)
JD.com, Inc. - Class A(a)	(3,409	)	(122,246	)
QuantumScape Corp.(a)	(99,100	)	(1,653,979	)
Rivian Automotive, Inc. - Class A(a)	(60,400	)	(3,970,696	)
			(5,746,921	)
Health Care (1.46%)
Atara Biotherapeutics, Inc.(a)	(54,200	)	(832,512	)
Bluebird Bio, Inc.(a)	(109,600	)	(864,744	)
Deciphera Pharmaceuticals, Inc.(a)	(93,300	)	(786,519	)
TG Therapeutics, Inc.(a)	(56,480	)	(653,473	)
			(3,137,248	)

SCHEDULE OF SECURITIES SOLD SHORT (continued)	Shares			Value
Industrials (1.06%)
Snap-on, Inc.(a)	(10,920	)	$	(2,274,090	)
Information Technology (7.40%)
Atlassian Corp. PLC - Class A(a)	(6,600	)		(2,140,644	)
International Business Machines Corp.(a)	(53,300	)		(7,119,281	)
MongoDB, Inc.(a)	(2,380	)		(964,162	)
Monolithic Power Systems, Inc.(a)	(4,640	)		(1,869,595	)
Wolfspeed, Inc.(a)	(19,100	)		(1,799,984	)
Zscaler, Inc.(a)	(7,800	)		(2,005,458	)
				(15,899,124	)
TOTAL COMMON STOCKS
(Proceeds $27,323,625)				(27,057,383	)
EXCHANGE TRADED FUNDS (2.10%)
SPDR S&P® Biotech ETF	(48,400	)		(4,522,012	)
TOTAL EXCHANGE TRADED FUNDS
(Proceeds $4,626,144)				(4,522,012	)
TOTAL SECURITIES SOLD SHORT
(Proceeds $31,949,769)			$	(31,579,395	)

Investment Abbreviations:

FEDEF - Federal Funds Effective Rate

FEDEF Rates:

1D FEDEF - 1 Day FEDEF as of January 31, 2022 was 0.08%

^(a) Non-income producing security.

^(b) Pledged security; a portion or all of the security is pledged as collateral for securities sold short, total return swap contracts, or borrowings. As of January 31, 2022, the aggregate value of those securities was $272,370,033, representing 126.81% of net assets. (See Note 1)

^(c) Loaned security; a portion or all of the security is on loan as of January 31, 2022.

^(d) When sector categorization is categorized by industry, no industry exceeds the 25% maximum specified in the Statement of Additional Information.

^(e) Restricted Security (See Note 1).

^(f) All or a portion of the security is exempt from registration of the Securities Act of 1933.  These securities may be resold in transactions exempt from registration under Rule 144A, normally to qualified institutional buyers. As of January 31, 2022, these securities had an aggregate value of $3,372,907 or 1.57% of net assets.

^(g) Private Placement; these securities may only be resold in transactions exempt from registration under the Securities Act of 1933. As of January 31, 2022, these securities had an aggregate value of $3,426,639 or 1.59% of net assets.

^(h) As a result of the use of significant unobservable inputs to determine fair value, these investments have been classified as Level 3 assets. (See Note 1)

⁽ⁱ⁾ Fair valued security; valued by management in accordance with procedures approved by the Board. As of January 31, 2022, these securities had an aggregate value of $3,426,639 or 1.59% of total net assets.

^(j) Includes cash which is being held as collateral for futures contracts, total return swap contracts and securities sold short.

TOTAL RETURN SWAP CONTRACTS 

Counter Party	Reference Entity/Obligation	Notional Amount		Floating Rate Paid by the Fund*	Floating Rate Index	Termination  Date	Value		Net Unrealized Appreciation
Morgan Stanley	Goertek, Inc.	$	4,680,345	1D FEDEF -250 bps	1D FEDEF	1/8/2024	$	4,097,416	$	582,929
Morgan Stanley	BYD Co., Ltd.		9,158,001	1D FEDEF -250 bps	1D FEDEF	1/8/2024		7,297,108		1,860,893
Morgan Stanley	Contemporary Amperex Technology Co., Ltd.		9,033,495	1D FEDEF - 250 bps	1D FEDEF	1/8/2024		8,797,740		235,754
		$	22,871,841				$	20,192,264	$	2,679,576

Counter Party	Reference Entity/Obligation	Notional Amount		Floating Rate Paid by the Fund*	Floating Rate Index	Termination  Date	Value		Net Unrealized Depreciation
Morgan Stanley	Luxshare Precision Industry Co., Ltd.	$	4,063,614	1D FEDEF - 250 bps	1D FEDEF	1/8/2024	$	4,096,178	$	(32,564	)
TOTAL		$	26,935,455				$	24,288,442	$	2,647,012

CALL OPTIONS WRITTEN 

Underlying Security	Counterparty	Expiration Date	Strike Price		Contracts			Notional Amount		Value
S&P 500® Index	Morgan Stanley	03/18/2022	$	4,000		(215	)	$	97,084,325	$	(709,500	)
								$	97,084,325	$	(709,500	)

Clough Global Opportunities Fund

STATEMENT OF INVESTMENTS

January 31, 2022 (Unaudited)

	Shares		Value
COMMON STOCKS 109.95%
Communication Services 2.90%
Alphabet, Inc. - Class C(a)(b)		762	$	2,068,045
Netflix, Inc.(a)		4,360		1,862,331
ViacomCBS, Inc. - Class B(b)(c)		228,600		7,646,670
				11,577,046
Consumer Discretionary 16.00%
Amazon.com, Inc.(a)(b)(c)		8,623		25,795,446
Carnival Corp.(a)(b)(c)		253,270		5,017,279
DR Horton, Inc.(b)(c)		118,600		10,581,492
Lennar Corp. - Class A(b)(c)		75,979		7,302,342
Royal Caribbean Cruises Ltd.(a)(b)(c)		73,647		5,730,473
Tesla, Inc.(a)(b)(c)		10,013		9,379,377
				63,806,409
Financials 20.01%
Citigroup, Inc.(b)(c)		116,800		7,606,016
Equitable Holdings, Inc.(b)(c)		443,200		14,909,248
Fidelity National Financial, Inc.(b)(c)		185,650		9,347,477
First American Financial Corp.(b)(c)		295,270		22,000,568
PennyMac Financial Services, Inc.(b)		241,531		15,143,994
Starwood Property Trust, Inc.(b)(c)		435,400		10,776,150
				79,783,453
Health Care 34.40%(d)
Acadia Healthcare Co., Inc.(a)(b)(c)		72,140		3,798,171
Amphivena Therapeutics, Inc. - Series C(a)(e)(f)(g)(h)(i)		780,326		3,247,428
Apellis Pharmaceuticals, Inc.(a)(b)(c)		55,016		2,215,494
Arcellx, Inc. - Series B(a)(e)(f)(g)(h)(i)		969,881		2,026,081
Arcellx, Inc. - Series C(a)(e)(f)(g)(h)(i)		180,924		377,950
Arvinas, Inc.(a)(b)(c)		125,500		8,971,995
C4 Therapeutics, Inc.(a)(b)		156,881		3,832,603
Centrexion Therapeutics Corp.(a)(e)(g)(h)(i)		14,166		175,545
Centrexion Therapeutics Corp. - Series D Preferred Shares(a)(e)(f)(g)(h)(i)		217,952		2,700,861
Checkmate Pharmaceuticals, Inc.(a)(b)(c)		637,346		1,555,124
Community Health Systems, Inc.(a)(b)(c)		524,827		6,660,055
CRISPR Therapeutics AG(a)(b)(c)		46,798		2,983,373
Doximity, Inc. - Class A(a)(b)		76,040		3,465,143
Envista Holdings Corp.(a)(b)		164,400		7,108,656
HCA Healthcare, Inc.(b)(c)		16,870		4,049,643
Hologic, Inc.(a)(b)(c)		99,490		6,988,178
Jazz Pharmaceuticals PLC(a)(b)(c)		57,790		8,027,609
Johnson & Johnson(b)(c)		45,570		7,851,255
Kymera Therapeutics, Inc.(a)(b)(c)		100,744		4,231,248
Legend Biotech Corp. - ADR(a)(b)		112,791		4,809,408
McKesson Corp.(b)(c)		3,616		928,300
Merck & Co., Inc.(b)(c)		112,900		9,199,092
Mirati Therapeutics, Inc.(a)(b)(c)		23,220		2,770,146
Nurix Therapeutics, Inc.(a)(b)(c)		216,148		4,024,676

	Shares		Value
Health Care (continued)
Surgery Partners, Inc.(a)(b)	158,881	$	6,779,452
Teladoc Health, Inc.(a)(b)	41,370		3,173,493
Tenet Healthcare Corp.(a)(b)(c)	53,200		3,943,184
Thermo Fisher Scientific, Inc.(b)	6,548		3,806,352
UnitedHealth Group, Inc.(b)(c)	15,730		7,433,526
Vertex Pharmaceuticals, Inc.(a)(b)(c)	28,853		7,012,722
Zoetis, Inc.(b)	15,225		3,041,803
			137,188,566
Industrials 7.03%
Airbus SE(a)	75,828		9,551,336
The Boeing Co.(a)(b)	36,025		7,213,646
Hertz Global Holdings, Inc.(a)(b)	79,600		1,533,096
Raytheon Technologies Corp.(b)	58,000		5,231,020
TransDigm Group, Inc.(a)(b)(c)	7,333		4,518,521
			28,047,619
Information Technology 29.61%(d)
GoDaddy, Inc. - Class A(a)(b)	88,400		6,692,764
Infineon Technologies AG	293,974		12,000,118
Lam Research Corp.(b)(c)	10,750		6,341,640
MediaTek, Inc.	230,500		8,908,733
Micron Technology, Inc.(b)	319,200		26,260,584
Microsoft Corp.(b)(c)	86,680		26,955,746
NVIDIA Corp.	29,880		7,316,417
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(b)(c)	192,500		23,606,275
			118,082,277
TOTAL COMMON STOCKS
(Cost $427,722,960)			438,485,370
WARRANTS 0.98%(a)
Hertz Global Holdings, Inc., Strike Price $13.80, Expires 6/30/2051(b)(c)	318,034		3,908,638
TOTAL WARRANTS
(Cost $5,290,776)			3,908,638

Underlying Security/Expiration Date/ Exercise Price/Notional Amount	Contracts	Value
PURCHASED OPTIONS 0.66%
Put Options Purchased 0.66%
S&P 500® Index
03/18/22, $4,250, $180,170,445	399	2,627,415
Total Put Options Purchased
(Cost $5,166,660)		2,627,415

Description/Maturity Date/Rate		Principal Amount	Value
CORPORATE BONDS 5.94%
Financials
Golub Capital BDC, Inc.
08/24/2026, 2.500%(b)	$	4,130,000	3,982,738

Description/Maturity Date/Rate		Principal Amount		Value
CORPORATE BONDS (continued)
Main Street Capital Corp.
07/14/2026, 3.000%(b)	$	1,500,000	$	1,470,815
Nationstar Mortgage Holdings, Inc.
12/15/2030, 5.125%(b)(e)(f)		1,510,000		1,418,781
11/15/2031, 5.750%(e)(f)		2,500,000		2,420,600
Owl Rock Technology Finance Corp.
12/15/2025, 4.750%(b)(e)(f)		4,000,000		4,175,309
SVB Financial Group
Series D, Perpetual Maturity, 5Y US TI + 3.074%(b)(c)(j)(k)		4,000,000		3,945,000
				17,413,243
Industrials
Hexcel Corp.
08/15/2025, 4.950%(b)		1,000,000		1,067,478
02/15/2027, 4.200%(b)		5,000,000		5,210,856
				6,278,334
TOTAL CORPORATE BONDS
(Cost $24,442,206)				23,691,577
CONVERTIBLE CORPORATE BONDS 0.38%
Financials
Starwood Property Trust, Inc.
04/01/2023, 4.375%(b)(c)		1,200,000		1,246,396
Health Care
Amphivena Convertible Note PP
12/31/2049 (e)(f)(g)(h)(i)		253,750		253,750
TOTAL CONVERTIBLE CORPORATE BONDS
(Cost $1,460,948)				1,500,146
GOVERNMENT & AGENCY OBLIGATIONS 36.64%
U.S. Treasury Notes
08/31/2022, 1.625%(b)		10,000,000		10,062,007
11/15/2022, 1.625%(b)		13,000,000		13,096,487
01/31/2023, 0.125%(b)		20,000,000		19,863,486
09/30/2023, 0.250%(b)		15,000,000		14,798,437
12/31/2023, 0.750%(b)		56,000,000		55,566,875
01/31/2024, 0.875%		20,000,000		19,880,469
06/30/2024, 1.750%(b)		3,000,000		3,034,336
11/30/2026, 1.250%(b)		10,000,000		9,836,719
TOTAL GOVERNMENT & AGENCY OBLIGATIONS
(Cost $147,095,020)				146,138,816

	Shares	Value
SHORT-TERM INVESTMENTS 11.67%
Money Market Funds  11.67%
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.010% 7-day yield)	46,527,771	46,527,771
TOTAL SHORT-TERM INVESTMENTS
(Cost $46,527,771)		46,527,771

		Value
Total Investments - 166.22%
(Cost $657,706,341)	$	662,879,733
Liabilities in Excess of Other Assets - (66.22%)(l)		(264,085,069	)
NET ASSETS - 100.00%	$	398,794,664

SCHEDULE OF SECURITIES SOLD SHORT	Shares			Value
COMMON STOCKS (12.57%)
Consumer Discretionary (2.67%)
JD.com, Inc. - Class A(a)	(6,323	)		(226,741	)
QuantumScape Corp.(a)	(183,200	)		(3,057,608	)
Rivian Automotive, Inc. - Class A(a)	(111,900	)		(7,356,306	)
				(10,640,655	)
Health Care (1.46%)
Atara Biotherapeutics, Inc.(a)	(100,900	)		(1,549,824	)
Bluebird Bio, Inc.(a)	(204,100	)		(1,610,349	)
Deciphera Pharmaceuticals, Inc.(a)	(173,600	)		(1,463,448	)
TG Therapeutics, Inc.(a)	(105,120	)		(1,216,238	)
				(5,839,859	)
Industrials (1.06%)
Snap-on, Inc.(a)	(20,200	)		(4,206,650	)
Information Technology (7.38%)
Atlassian Corp. PLC - Class A(a)	(12,300	)		(3,989,382	)
International Business Machines Corp.(a)	(98,400	)		(13,143,288	)
MongoDB, Inc.(a)	(4,420	)		(1,790,586	)
Monolithic Power Systems, Inc.(a)	(8,580	)		(3,457,140	)
Wolfspeed, Inc.(a)	(35,300	)		(3,326,672	)
Zscaler, Inc.(a)	(14,500	)		(3,728,095	)
				(29,435,163	)
TOTAL COMMON STOCKS
(Proceeds $50,616,278)				(50,122,327	)
EXCHANGE TRADED FUNDS (2.11%)
SPDR S&P® Biotech ETF	(90,200	)		(8,427,386	)
TOTAL EXCHANGE TRADED FUNDS
(Proceeds $8,621,412)				(8,427,386	)
TOTAL SECURITIES SOLD SHORT
(Proceeds $59,237,690)			$	(58,549,713	)

Investment Abbreviations:

FEDEF - Federal Funds Effective Rate

TI - Treasury Index

FEDEF Rates:

1D FEDEF - 1 Day FEDEF as of January 31, 2022 was 0.08%

TI  Rates:

5Y TI as of January 31, 2022 was 1.62%  

^(a) Non-income producing security.

^(b) Pledged security; a portion or all of the security is pledged as collateral for securities sold short, total return swap contracts, or borrowings. As of January 31, 2022, the aggregate value of those securities was $504,632,049, representing 126.54% of net assets. (See Note 1)

^(c) Loaned security; a portion or all of the security is on loan as of January 31, 2022.

^(d) When sector categorization is categorized by industry, no industry exceeds the 25% maximum specified in the Statement of Additional Information.

^(e) Restricted Security (See Note 1).

^(f) Security is exempt from registration of the Securities Act of 1933.  These securities may be resold in transactions exempt from registration under Rule 144A, normally to qualified institutional buyers. As of January 31, 2022, these securities had an aggregate value of $16,620,760 or 4.17% of net assets.

^(g) Private Placement; these securities may only be resold in transactions exempt from registration under the Securities Act of 1933. As of January 31, 2022, these securities had an aggregate value of $8,781,615 or 2.20% of net assets.

^(h) As a result of the use of significant unobservable inputs to determine fair value, these investments have been classified as Level 3 assets. (See Note 1)

⁽ⁱ⁾ Fair valued security; valued by management in accordance with procedures approved by the Board. As of January 31, 2022, these securities had an aggregate value of $8,781,615 or 2.20% of total net assets.

^(j) Variable rate investment. Interest rates reset periodically. Interest rate shown reflects the rate in effect at January 31, 2022. For securities based on a published reference rate and spread, the reference rate and spread are indicated in the description above.

^(k) This security has no contractual maturity date, is not redeemable and contractually pays an indefinite stream of interest.

^(l) Includes cash which is being held as collateral for futures contracts, total return swap contracts and securities sold short.

TOTAL RETURN SWAP CONTRACTS

Counter Party	Reference Entity/Obligation	Notional Amount		Floating Rate Paid by the Fund*	Floating Rate Index	Termination  Date	Value		Net Unrealized Appreciation
Morgan Stanley	Goertek, Inc.	$	8,641,580	1D FEDEF -250 bps	1D FEDEF	1/8/2024	$	7,564,801	$	1,076,779
Morgan Stanley	BYD Co., Ltd.		16,987,912	1D FEDEF -250 bps	1D FEDEF	1/8/2024		13,535,991		3,451,921
Morgan Stanley	Contemporary Amperex Technology Co., Ltd.		16,761,494	1D FEDEF - 250 bps	1D FEDEF	1/8/2024		16,326,745		434,749
		$	42,390,986				$	37,427,537	$	4,963,449

Counter Party	Reference Entity/Obligation	Notional Amount		Floating Rate Paid by the Fund*	Floating Rate Index	Termination  Date	Value		Net Unrealized Depreciation
Morgan Stanley	Luxshare Precision Industry Co., Ltd.	$	7,530,934	1D FEDEF - 250 bps	1D FEDEF	1/8/2024	$	7,591,271	$	(60,337	)
TOTAL		$	49,921,920				$	45,018,808	$	4,903,112

CALL OPTIONS WRITTEN

Underlying Security	Counterparty	Expiration Date	Strike Price		Contracts			Notional Amount		Value
S&P 500® Index	Morgan Stanley	03/18/2022	$	4,000		(399	)	$	180,170,445	$	(1,316,700	)
								$	180,170,445	$	(1,316,700	)

For Fund compliance purposes, the Fund’s sector classifications refer to any one of the sector sub-classifications used by one or more widely recognized market indexes, and/or as defined by Fund management. This definition may not apply for purposes of this report, which may combine sector sub-classifications for reporting ease. Sectors are shown as a percent of net assets. These sector classifications are unaudited.

See Notes to Quarterly Statement of Investments. 

Clough Global FundS

Notes to Quarterly Statement of Investments

January 31, 2022 (unaudited)

1. Organization and SIGNIFICANT ACCOUNTING AND OPERATING POLICIES

Clough Global Dividend and Income Fund, Clough Global Equity Fund, and Clough Global Opportunities Fund (each a “Fund”, collectively the “Funds”), are closed-end management investment companies registered under the Investment Company Act of 1940 (the “1940 Act”). The Funds were organized under the laws of the state of Delaware on April 27, 2004, January 25, 2005, and January 12, 2006, respectively for Clough Global Dividend and Income Fund, Clough Global Equity Fund, and Clough Global Opportunities Fund. The Funds were previously registered as non-diversified investment companies. As a result of ongoing operations, each of the Funds became a diversified company. The Funds may not resume operating in a non-diversified manner without first obtaining shareholder approval. Each Fund’s investment objective is to provide a high level of total return. Each Declaration of Trust provides that the Board of Trustees (the “Board”) may authorize separate classes of shares of beneficial interest. The common shares of Clough Global Dividend and Income Fund, Clough Global Equity Fund, and Clough Global Opportunities Fund are listed on the NYSE American LLC and trade under the ticker symbols “GLV”, “GLQ” and “GLO” respectively.

The following is a summary of significant accounting policies followed by the Funds. These policies are in conformity with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures, including the disclosure of contingent assets and liabilities, in the financial statements during the reporting period. Management believes the estimates and security valuations are appropriate; however, actual results may differ from those estimates, and the security valuations reflected in the financial statements may differ from the value the Funds ultimately realize upon sale of the securities. Each Fund is considered an investment company for financial reporting purposes under GAAP and follows the accounting and reporting guidance applicable to investment companies as codified in Accounting Standards Codification (“ASC”) Topic 946, Financial Services – Investment Companies.

The net asset value (“NAV”) per share of each Fund is determined no less frequently than daily, on each day that the New York Stock Exchange (“NYSE” or the “Exchange”) is open for trading, as of the close of regular trading on the Exchange (normally 4:00 p.m. New York time). Trading may take place in foreign issues held by a Fund at times when the Fund is not open for business. As a result, each Fund’s NAV may change at times when it is not possible to purchase or sell shares of that Fund.

Investment Valuation: Securities, held by each Fund, for which exchange quotations are readily available, are valued at the last sale price, or if no sale price or if traded on the over-the-counter market, at the mean of the bid and asked prices on such day. Money market funds are valued based on the closing NAV. Most securities listed on a foreign exchange are valued at the last sale price at the close of the exchange on which the security is primarily traded. In certain countries market maker prices are used since they are the most representative of the daily trading activity. Market maker prices are usually the mean between the bid and ask prices. Certain markets are not closed at the time that the Funds price their portfolio securities. In these situations, snapshot prices are provided by the individual pricing services or other alternate sources at the close of the NYSE as appropriate. Securities not traded on a particular day are valued at the mean between the last reported bid and the asked quotes, or the last sale price when appropriate; otherwise fair value will be determined by the Board-appointed fair valuation committee. Debt securities for which the over-the-counter market is the primary market are normally valued on the basis of prices furnished by one or more pricing services or dealers at the mean between the latest available bid and asked prices. As authorized by the Board, debt securities (including short-term obligations that will mature in 60 days or less) may be valued on the basis of valuations furnished by a pricing service which determines valuations based upon market transactions for normal, institutional-size trading units of securities or a matrix method which considers yield or price of comparable bonds provided by a pricing service. Over-the-counter options are valued at the mean between bid and asked prices provided by dealers. Exchange-traded options are valued at closing settlement prices. Total return swaps are priced based on valuations provided by a Board approved independent third party pricing agent. If a total return swap price cannot be obtained from an independent third party pricing agent the Fund shall seek to obtain a bid price from at least one independent and/or executing broker. Futures are valued at settlement prices.

If the price of a security is unavailable in accordance with the aforementioned pricing procedures, or the price of a security is unreliable, e.g., due to the occurrence of a significant event, the security may be valued at its fair value determined by management pursuant to procedures adopted by the Board. For this purpose, fair value is the price that a Fund reasonably expects to receive on a current sale of the security. Due to the number of variables affecting the price of a security, however; it is possible that the fair value of a security may not accurately reflect the price that a Fund could actually receive on a sale of the security.

A three-tier hierarchy has been established to classify fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability that are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability that are developed based on the best information available.

Various inputs are used in determining the value of each Fund’s investments as of the reporting period end. These inputs are categorized in the following hierarchy under applicable financial accounting standards:

Level 1 – Unadjusted quoted prices in active markets for identical, unrestricted assets or liabilities that a Fund has the ability to access at the measurement date;

Level 2 – Quoted prices which are not active, quoted prices for similar assets or liabilities in active markets or inputs other than quoted prices that are observable (either directly or indirectly) for substantially the full term of the asset or liability; and

Level 3 – Significant unobservable prices or inputs (including the Fund’s own assumptions in determining the fair value of investments) where there is little or no market activity for the asset or liability at the measurement date.

The following is a summary of the inputs used as of January 31, 2022, in valuing each Fund’s investments carried at value. 

Clough Global Dividend and Income Fund                     

Investments in Securities at Value*		Level 1		Level 2		Level 3		Total
Common Stocks	$	94,154,680	$	–	$	–	$	94,154,680
Preferred Stocks		1,133,538		–		–		1,133,538
Purchased Options		704,595		–		–		704,595
Corporate Bonds		–		14,072,681		–		14,072,681
Convertible Corporate Bonds		–		3,285,604		–		3,285,604
Asset-Backed Securities		–		41,326		–		41,326
Government & Agency Obligations		–		58,381,202		–		58,381,202
Short-Term Investments		8,314,571		–		–		8,314,571
TOTAL	$	104,307,384	$	75,780,813	$	–	$	180,088,197

Other Financial Instruments		Level 1			Level 2			Level 3		Total
Assets
Total Return Swap Contracts**		–			1,514,342			–		1,514,342
Liabilities
Written Options		(353,100	)		–			–		(353,100	)
Securities Sold Short
Common Stocks		(11,371,201	)		–			–		(11,371,201	)
Exchange Traded Funds		(2,223,634	)		–			–		(2,223,634	)
Total Return Swap Contracts**		–			(15,653	)		–		(15,653	)
TOTAL	$	(13,947,935	)	$	1,498,689		$	–	$	(12,449,246	)

Clough Global Equity Fund                         

Investments in Securities at Value*		Level 1		Level 2		Level 3		Total
Common Stocks
Communication Services	$	7,417,976	$	–	$	–	$	7,417,976
Consumer Discretionary		35,254,692		–		–		35,254,692
Financials		46,451,515		–		–		46,451,515
Health Care		72,100,183		–		3,317,889		75,418,072
Industrials		17,356,658		–		–		17,356,658
Information Technology		63,759,424		–		–		63,759,424
Warrants		2,108,841		–		–		2,108,841
Purchased Options		1,415,775		–		–		1,415,775
Convertible Corporate Bonds		–		–		108,750		108,750
Government & Agency Obligations		–		82,243,629		–		82,243,629
Short-Term Investments		26,649,816		–		–		26,649,816
TOTAL	$	272,514,880	$	82,243,629	$	3,426,639	$	358,185,148

Other Financial Instruments		Level 1			Level 2			Level 3		Total
Assets
Total Return Swap Contracts**		–			2,679,576			–		2,679,576
Liabilities
Written Options		(709,500	)		–			–		(709,500	)
Securities Sold Short
Common Stocks		(27,057,383	)		–			–		(27,057,383	)
Exchange Traded Funds		(4,522,012	)		–			–		(4,522,012	)
Total Return Swap Contracts**		–			(32,564	)		–		(32,564	)
TOTAL	$	(32,288,895	)	$	2,647,012		$	–	$	(29,641,883	)

Clough Global Opportunities Fund                     

Investments in Securities at Value*	Level 1		Level 2		Level 3		Total
Common Stocks
Clough Global Opportunities Fund (continued)
Investments in Securities at Value*		Level 1		Level 2		Level 3		Total
Communication Services	$	11,577,046	$	–	$	–	$	11,577,046
Consumer Discretionary		63,806,409		–		–		63,806,409
Financials		79,783,453		–		–		79,783,453
Health Care		128,660,701		–		8,527,865		137,188,566
Industrials		28,047,619		–		–		28,047,619
Information Technology		118,082,277		–		–		118,082,277
Warrants		3,908,638		–		–		3,908,638
Purchased Options		2,627,415		–		–		2,627,415
Corporate Bonds		–		23,691,577		–		23,691,577
Convertible Corporate Bonds		–		1,246,396		253,750		1,500,146
Government & Agency Obligations		–		146,138,816		–		146,138,816
Short-Term Investments		46,527,771		–		–		46,527,771
TOTAL	$	483,021,329	$	171,076,789	$	8,781,615	$	662,879,733

Other Financial Instruments		Level 1			Level 2			Level 3		Total
Assets
Total Return Swap Contracts**		–			4,963,449			–		4,963,449
Liabilities
Written Options		(1,316,700	)		–			–		(1,316,700	)
Securities Sold Short
Common Stocks		(50,122,327	)		–			–		(50,122,327	)
Exchange Traded Funds		(8,427,386	)		–			–		(8,427,386	)
Total Return Swap Contracts**		–			(60,337	)		–		(60,337	)
TOTAL	$	(59,866,413	)	$	4,903,112		$	–	$	(54,963,301	)

* For detailed sector descriptions, see the accompanying Statements of Investments.

** Futures contracts and swap contracts are reported at their unrealized appreciation/(depreciation) at measurement date, which represents the change in the contract's value from trade date.

In the event a Board approved independent pricing service is unable to provide an evaluated price for a security or Clough Capital Partners L.P. (the “Adviser” or “Clough”) believes the price provided is not reliable, securities of each Fund may be valued at fair value as described above. In these instances the Adviser may seek to find an alternative independent source, such as a broker/dealer to provide a price quote, or by using evaluated pricing models similar to the techniques and models used by the independent pricing service. These fair value measurement techniques may utilize unobservable inputs (Level 3).

On a monthly basis, the Fair Value Committee of each Fund meets and discusses securities that have been fair valued during the preceding month in accordance with the Funds’ Fair Value Procedures and reports quarterly to the Board on the results of those meetings.

The following is a reconciliation of the investments in which significant unobservable inputs (Level 3) were used in determining fair value:

Clough Global Equity Fund
Investments in Securities	Balance as of October 31, 2021		Realized Gain/(Loss)		Change in Unrealized Appreciation/ (Depreciation)			Purchases		Sales Proceeds		Transfer into Level 3		Transfer out of Level 3		Balance as of   January 31, 2022		Net change in unrealized appreciation/ (depreciation) attributable to Level 3 investments held at January 31, 2022
Common Stocks	$	3,365,735	$	–	$	(47,846	)	$	–	$	–	$	–	$	–	$	3,317,889	$	(47,846	)
Convertible Corporate Bond		108,750		–		–			–		–		–		–		108,750		–
Total	$	3,474,485	$	–	$	(47,846	)	$	–	$	–	$	–	$	–	$	3,426,639	$	(47,846	)

Clough Global Opportunities Fund
Investments in Securities	Balance as of October 31, 2021		Realized Gain/(Loss)		Change in Unrealized Appreciation/ (Depreciation)			Purchases		Sales Proceeds		Transfer into Level 3		Transfer out of Level 3		Balance as of January 31, 2022		Net change in unrealized appreciation/ (depreciation) attributable to Level 3 investments held at January 31, 2022
Common Stocks	$	8,656,565	$	–	$	(128,700	)	$	–	$	–	$	–	$	–	$	8,527,865	$	(115,492	)
Convertible Corporate Bond		253,750		–		–			–		–		–		–		253,750		–
Total	$	8,910,315	$	–	$	(128,700	)	$	–	$	–	$	–	$	–	$	8,725,989	$	(115,492	)

The following is a summary of valuation techniques and quantitative information used in determining the fair value of the Fund’s Level 3 investments at January 31, 2022:

Fund	Sector	Fair Value		Valuation Technique	Unobservable Input(a)	Range/Premium
Clough Global Equity Fund	Health Care	$	108,750	Accomplishment & Goals and Index Performance Method	Transaction Price	N/A
		$	3,317,889	Common Stock Equivalent	Transaction Price	N/A
Clough Global Opportunities Fund	Health Care	$	253,750	Accomplishment & Goals and Index Performance Method	Transaction Price	N/A
		$	8,527,865	Common Stock Equivalent	Transaction Price	N/A

^(a) A change to the unobservable input may result in a significant change to the value of the investment as follows:

Unobservable Input	Impact to Value if Input Increases	Impact to Value if Input Decreases
Transaction Price	Increase	Decrease

Foreign Securities: Each Fund may invest a portion of its assets in foreign securities. In the event that a Fund executes a foreign security transaction, the Fund will generally enter into a foreign currency spot contract to settle the foreign security transaction. Foreign securities may carry more risk than U.S. securities, such as political, market and currency risks.

The accounting records of each Fund are maintained in U.S. dollars. Prices of securities denominated in foreign currencies are translated into U.S. dollars at the closing rates of exchange at period end. Amounts related to the purchase and sale of foreign securities and investment income are translated at the rates of exchange prevailing on the respective dates of such transactions.

A foreign currency spot contract is a commitment to purchase or sell a foreign currency at a future date, at a negotiated rate. Each Fund may enter into foreign currency spot contracts to settle specific purchases or sales of securities denominated in a foreign currency and for protection from adverse exchange rate fluctuation. Risks to a Fund include the potential inability of the counterparty to meet the terms of the contract.

Exchange Traded Funds: Each Fund may invest in Exchange Traded Funds (“ETFs”), which are funds whose shares are traded on a national exchange. ETFs may be based on underlying equity or fixed income securities, as well as commodities or currencies. ETFs do not sell individual shares directly to investors and only issue their shares in large blocks known as “creation units.” The investor purchasing a creation unit then sells the individual shares on a secondary market. Although similar diversification benefits may be achieved through an investment in another investment company, ETFs generally offer greater liquidity and lower expenses. Because an ETF incurs its own fees and expenses, shareholders of a Fund investing in an ETF will indirectly bear those costs. Such Funds will also incur brokerage commissions and related charges when purchasing or selling shares of an ETF. Unlike typical investment company shares, which are valued once daily, shares in an ETF may be purchased or sold on a securities exchange throughout the trading day at market prices that are generally close to the NAV of the ETF.

Short Sales: Each Fund may sell a security it does not own in anticipation of a decline in the fair value of that security. When a Fund sells a security short, it must borrow the security sold short and deliver it to the broker-dealer through which it made the short sale. A gain, limited to the price at which a Fund sold the security short, or a loss, unlimited in size, will be recognized upon the termination of the short sale.

Each Fund's obligation to replace the borrowed security will be secured by collateral deposited with the broker-dealer, usually cash, U.S. government securities or other liquid securities. Each Fund will also be required to designate on its books and records similar collateral with its custodian to the extent, if any, necessary so that the aggregate collateral value is at all times at least equal to the current value of the security sold short. The cash amount is reported on the Statements of Assets and Liabilities as Deposit with broker for securities sold short which is held with one counterparty. Each Fund is obligated to pay interest to the broker for any debit balance of the margin account relating to short sales. The interest incurred by the Funds is reported on the Statements of Operations as Interest expense – margin account. Interest amounts payable, if any, are reported on the Statements of Assets and Liabilities as Interest payable – margin account.

Each Fund may also sell a security short if it owns at least an equal amount of the security sold short or another security convertible or exchangeable for an equal amount of the security sold short without payment of further compensation (a short sale against-the-box). In a short sale against-the-box, the short seller is exposed to the risk of being forced to deliver stock that it holds to close the position if the borrowed stock is called in by the lender, which would cause gain or loss to be recognized on the delivered stock. Each Fund expects normally to close its short sales against-the-box by delivering newly acquired stock.

Derivatives Instruments and Hedging Activities: The following discloses the Funds’ use of derivative instruments and hedging activities.

The Funds’ investment objectives not only permit the Funds to purchase investment securities, they also allow the Funds to enter into various types of derivative contracts, including, but not limited to, purchased and written options, swaps, futures and warrants. In doing so, the Funds will employ strategies in differing combinations to permit them to increase, decrease, or change the level or types of exposure to market factors. Central to those strategies are features inherent to derivatives that make them more attractive for this purpose than equity securities; they require little or no initial cash investment, they can focus exposure on only certain selected risk factors, and they may not require the ultimate receipt or delivery of the underlying security (or securities) to the contract. This may allow the Funds to pursue their objectives more quickly and efficiently than if they were to make direct purchases or sales of securities capable of affecting a similar response to market factors.

Risk of Investing in Derivatives: The Funds’ use of derivatives can result in losses due to unanticipated changes in the market risk factors and the overall market. In instances where the Funds are using derivatives to decrease or hedge exposures to market risk factors for securities held by the Funds, there are also risks that those derivatives may not perform as expected, resulting in losses for the combined or hedged positions.

Derivatives may have little or no initial cash investment relative to their market value exposure and therefore can produce significant gains or losses in excess of their cost. This use of embedded leverage allows the Funds to increase their market value exposure relative to their net assets and can substantially increase the volatility of the Funds’ performance.

Additional associated risks from investing in derivatives also exist and potentially could have significant effects on the valuation of the derivative and the Funds. Typically, the associated risks are not the risks that the Funds are attempting to increase or decrease exposure to, per their investment objectives, but are the additional risks from investing in derivatives.

Examples of these associated risks are liquidity risk, which is the risk that the Funds will not be able to sell the derivative in the open market in a timely manner, and counterparty credit risk, which is the risk that the counterparty will not fulfill its obligation to the Funds. Associated risks can be different for each type of derivative and are discussed by each derivative type in the notes that follow.

Each Fund may acquire put and call options and options on stock indices and enter into stock index futures contracts, certain credit derivatives transactions and short sales in connection with its equity investments. In connection with a Fund's investments in debt securities, it may enter into related derivatives transactions such as interest rate futures, swaps and options thereon and certain credit derivatives transactions. Derivatives transactions of the types described above subject a Fund to increased risk of principal loss due to imperfect correlation or unexpected price or interest rate movements. Each Fund also will be subject to credit risk with respect to the counterparties to the derivatives contracts purchased by a Fund. If a counterparty becomes bankrupt or otherwise fails to perform its obligations under a derivatives contract due to financial difficulties, each Fund may experience significant delays in obtaining any recovery under the derivatives contract in a bankruptcy or other reorganization proceeding. Each Fund may obtain only a limited recovery or may obtain no recovery in such circumstances.

Market Risk Factors: In addition, in pursuit of their investment objectives, certain Funds may seek to use derivatives, which may increase or decrease exposure to the following market risk factors:

Equity Risk: Equity risk relates to the change in value of equity securities as they relate to increases or decreases in the general market.

Foreign Exchange Rate Risk: Foreign exchange rate risk relates to the change in the U.S. dollar value of a security held that is denominated in a foreign currency. The value of a foreign currency denominated security will decrease as the dollar appreciates against the currency, while the value of the foreign currency denominated security will increase as the dollar depreciates against the currency.

Option Writing/Purchasing: Each Fund may purchase or write (sell) put and call options. One of the risks associated with purchasing an option among others, is that a Fund pays a premium whether or not the option is exercised. Additionally, a Fund bears the risk of loss of premium and change in value should the counterparty not perform under the contract. The cost of securities acquired through the exercise of call options is increased by premiums paid. The proceeds from securities sold through the exercise of put options are decreased by the premiums paid. Each Fund is obligated to pay interest to the broker for any debit balance of the margin account relating to options. Each Fund pledges cash or liquid assets as collateral to satisfy the current obligations with respect to written options.

When a Fund writes an option, an amount equal to the premium received by a Fund is recorded as a liability and is subsequently adjusted to the current value of the option written. Premiums received from writing options that expire unexercised are treated by a Fund on the expiration date as realized gains. The difference between the premium received and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is recorded as a realized gain or loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether a Fund has realized a gain or loss. If a put option is exercised, the premium reduces the cost basis of the securities purchased by a Fund. Each Fund, as writer of an option, bears the market risk of an unfavorable change in the price of the security underlying the written option. The Funds engaged in purchased and written options during the reporting period ended January 31, 2022.

Futures Contracts: Each Fund may enter into futures contracts. A futures contract is an agreement to buy or sell a security or currency (or to deliver a final cash settlement price in the case of a contract relating to an index or otherwise not calling for physical delivery at the end of trading in the contract) for a set price at a future date. If a Fund buys a security futures contract, the Fund enters into a contract to purchase the underlying security and is said to be "long" under the contract. If a Fund sells a security futures contact, the Fund enters into a contract to sell the underlying security and is said to be "short" under the contract. The price at which the contract trades (the "contract price") is determined by relative buying and selling interest on a regulated exchange. Futures contracts are marked to market daily and an appropriate payable or receivable for the change in value (“variation margin”) is recorded by the Fund. Such payables or receivables are recorded for financial statement purposes as variation margin payable or variation margin receivable by each Fund. Each Fund pledges cash or liquid assets as collateral to satisfy the current obligations with respect to futures contracts. Management has reviewed the futures agreement under which the futures contracts are traded and has determined that the Funds do not have the right to set-off, and therefore the futures contracts are not subject to enforceable netting arrangements.

The Funds enter into such transactions for hedging and other appropriate risk-management purposes or to increase return. While a Fund may enter into futures contracts for hedging purposes, the use of futures contracts might result in a poorer overall performance for the Fund than if it had not engaged in any such transactions. If, for example, the Fund had insufficient cash, it might have to sell a portion of its underlying portfolio of securities in order to meet daily variation margin requirements on its futures contracts or options on futures contracts at a time when it might be disadvantageous to do so. There may be an imperfect correlation between the Funds’ portfolio holdings and futures contracts entered into by the Fund, which may prevent the Fund from achieving the intended hedge or expose the Fund to risk of loss.

Futures contract transactions may result in losses substantially in excess of the variation margin. There can be no guarantee that there will be a correlation between price movements in the hedging vehicle and in the portfolio securities being hedged. An incorrect correlation could result in a loss on both the hedged securities in a Fund and the hedging vehicle so that the portfolio return might have been greater had hedging not been attempted. There can be no assurance that a liquid market will exist at a time when the Fund seeks to close out a futures contract. Lack of a liquid market for any reason may prevent a Fund from liquidating an unfavorable position, and the Fund would remain obligated to meet margin requirements until the position is closed. In addition, the Fund could be exposed to risk if the counterparties to the contracts are unable to meet the terms of their contracts. With exchange-traded futures contracts, there is minimal counterparty credit risk to the Funds since futures contracts are exchange-traded and the exchange’s clearinghouse, as counterparty to all exchange-traded futures contracts, guarantees the futures contracts against default. The Funds invested in futures during the reporting period ended January 31, 2022.

Swaps: A swap is an agreement that obligates two parties to exchange a series of cash flows at specified intervals based upon or calculated by reference to changes in specified prices or rates for a specified amount of an underlying asset. Each Fund may utilize swap agreements as a means to gain exposure to certain assets and/or to “hedge” or protect the Fund from adverse movements in securities prices or interest rates. Each Fund is subject to equity risk and interest rate risk in the normal course of pursuing its investment objective through investments in swap contracts. Swap agreements entail the risk that a party will default on its payment obligation to a Fund. If the other party to a swap defaults, a Fund would risk the loss of the net amount of the payments that it contractually is entitled to receive. If each Fund utilizes a swap at the wrong time or judges market conditions incorrectly, the swap may result in a loss to the Fund and reduce the Fund’s total return.

Total return swaps involve an exchange by two parties in which one party makes payments based on a set rate, either fixed or variable, while the other party makes payments based on the return of an underlying asset, which includes both the income it generates and any capital gains over the payment period. A Fund’s maximum risk of loss from counterparty risk or credit risk is the discounted value of the payments to be received from/paid to the counterparty over the contract’s remaining life, to the extent that the amount is positive. The risk is mitigated by having a netting arrangement between a Fund and the counterparty and by the posting of collateral to a Fund to cover the Fund’s exposure to the counterparty. Each Fund pledges cash or liquid assets as collateral to satisfy the current obligations with respect to swap contracts.

International Swaps and Derivatives Association, Inc. Master Agreements (“ISDA Master Agreements”) govern OTC financial derivative transactions entered into by a Fund and those counterparties. The ISDA Master Agreements maintain provisions for general obligations, representations, agreements, collateral and events of default or termination. Events of termination include conditions that may entitle counterparties to elect to terminate early and cause settlement of all outstanding transactions under the applicable ISDA Master Agreement. Any election to early terminate could be material to the financial statements. During the period ended January 31, 2022, the Funds invested in swap agreements consistent with the Funds’ investment strategies to gain exposure to certain markets or indices.

Warrants/Rights: Each Fund may purchase or otherwise receive warrants or rights. Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a set price. Funds typically use warrants and rights in a manner similar to their use of purchased options on securities, as described in options above. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of purchased options. However, warrants and rights often do not have standardized terms, and may have longer maturities and may be less liquid than exchange-traded options. In addition, the terms of warrants or rights may limit each Fund’s ability to exercise the warrants or rights at such times and in such quantities as each Fund would otherwise wish. During the period ended January 31, 2022, each Fund held rights and did not hold warrants. As of the period ended January 31, 2022, the Funds held no warrants or rights.

Restricted Securities: Although the Funds will invest primarily in publicly traded securities, they may invest a portion of their assets (generally, 10% of its value) in restricted securities. Restricted securities are securities that may not be sold to the public without an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") or, if they are unregistered, may be sold only in a privately negotiated transaction or pursuant to an exemption from registration.

Restricted securities as of January 31, 2022 were as follows:

Fund	Security	% of Net Assets			Acquisition Date	Shares		Cost		Value
Clough Global Dividend and Income Fund	Carvana Co.		0.42	%	11/16/2020		500,000		503,879		475,092
	Carvana Co.		0.83	%	9/25/2020		1,000,000		989,194		941,245
	Melco Resorts Finance, Ltd.		0.21	%	9/21/2020		250,000		259,203		240,354
	Nationstar Mortgage Holdings, Inc.		1.24	%	3/16/2021 - 6/28/2021		1,500,000		1,498,789		1,409,385
	Nationstar Mortgage Holdings, Inc.		0.42	%	11/16/2021		500,000		500,000		484,120
	Owl Rock Technology Finance Corp.		0.92	%	5/14/2021		1,000,000		1,067,246		1,043,827
	Owl Rock Technology Finance Corp.		0.97	%	12/13/2021		1,000,000		1,134,036		1,104,805
Total			5.00	%					5,952,347		5,698,828
Clough Global Equity Fund	Amphivena Therapeutics, Inc.		0.65	%	4/8/2019		334,425		1,199,997		1,391,753
	Amphivena Therapeutics, Inc.		0.05	%	8/27/2021		108,750		108,750		108,750
	Arcellx, Inc. Series B		0.41	%	8/8/2019 - 12/22/2020		421,845		731,625		881,234
	Arcellx, Inc. Series C		0.08	%	3/26/2021		78,692		165,017		164,388
	Centrexion Therapeutics Corp.		0.38	%	12/18/2017		66,719		701,250		826,782
	Centrexion Therapeutics Corp.		0.03	%	3/19/2019		4,336		48,741		53,732
Total			1.60	%					2,955,380		3,426,639
Clough Global Opportunities Fund	Amphivena Therapeutics, Inc.		0.81	%	4/8/2019		780,326		2,799,997		3,247,428
	Amphivena Therapeutics, Inc.		0.06	%	8/27/2021		253,750		253,750		253,750
	Arcellx, Inc. Series B		0.51	%	8/8/2019 - 12/22/2020		969,881		1,682,109		2,026,081
	Arcellx, Inc. Series C		0.09	%	3/26/2021		180,924		379,398		377,950
	Centrexion Therapeutics Corp.		0.04	%	3/19/2019		14,166		159,240		175,545
	Centrexion Therapeutics Corp.		0.68	%	12/18/2017		217,952		2,290,759		2,700,861
	Nationstar Mortgage Holdings, Inc.		0.36	%	6/28/2021		1,510,000		1,510,000		1,418,781
	Nationstar Mortgage Holdings, Inc.		0.61	%	11/22/2021		2,500,000		2,500,000		2,420,600
	Owl Rock Technology Finance Corp.		1.05	%	12/13/2021		4,000,000		4,268,983		4,175,309
Total			4.21	%					15,844,236		16,796,305

Counterparty Risk: Each of the Funds run the risk that the issuer or guarantor of a fixed income security, the counterparty to an over-the-counter derivatives contract, a borrower of each Fund’s securities or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to make timely principal, interest, or settlement payments or otherwise honor its obligations. In addition, to the extent that each of the Funds use over-the-counter derivatives, and/or has significant exposure to a single counterparty, this risk will be particularly pronounced for each of the Funds.

Other Risk Factors: Investing in the Funds may involve certain risks including, but not limited to, the following:

Unforeseen developments in market conditions may result in the decline of prices of, and the income generated by, the securities held by the Funds. These events may have adverse effects on the Funds such as a decline in the value and liquidity of many securities held by the Funds, and a decrease in NAV. Such unforeseen developments may limit or preclude the Funds’ ability to achieve their investment objective.

Investing in stocks may involve larger price fluctuation and greater potential for loss than other types of investments. This may result in the securities held by the Funds being subject to larger short-term declines in value compared to other types of investments.

The Funds may have elements of risk due to their investments in foreign issuers located in various countries outside the U.S. Such investments may subject the Funds to additional risks resulting from future political or economic conditions and/or possible impositions of adverse foreign governmental laws or currency exchange restrictions. Investments in securities of non-U.S. issuers have unique risks not present in securities of U.S. issuers, such as greater price volatility and less liquidity.

Fixed income securities are subject to credit risk, which is the possibility that a security could have its credit rating downgraded or that the issuer of the security could fail to make timely payments or default on payments of interest or principal. Additionally, fixed income securities are subject to interest rate risk, meaning the decline in the price of debt securities that accompanies a rise in interest rates. Bonds with longer maturities are subject to greater price fluctuations than bonds with shorter maturities.

The Funds invest in bonds which are rated below investment grade. These high yield bonds may be more susceptible than higher grade bonds to real or perceived adverse economic or industry conditions. The secondary market, on which high yield bonds are traded, may also be less liquid than the market for higher grade bonds.

A novel coronavirus and the resulting COVID-19 respiratory infection have resulted in a global pandemic and major disruption to economies and markets around the world. The pandemic has led to extreme short-term market volatility and may have adverse long-term effects on U.S. and world economies. Liquidity for many instruments has been reduced, and some sectors of the economy and individual issuers have experienced particularly large losses. The economic impacts of the global pandemic may adversely impact the Funds’ ability to reach their investment objectives and may adversely affect the value and liquidity of the Funds’ investments. Because of uncertainties in valuation, values reflected in these financial statements may differ from the value received upon sales of those investments. These circumstances may continue for an extended period of time, and may adversely affect the value and liquidity of the Funds’ investments.

2. CommitTed facility agreement

Each Fund entered into a financing package that includes a Committed Facility Agreement (the “Agreement”) dated January 16, 2009, as amended, between each Fund and BNP Paribas Prime Brokerage, Inc. (“BNP”) that allows each Fund to borrow funds from BNP. Each Fund entered a Special Custody and Pledge Agreement (the “Pledge Agreement”) dated December 9, 2013, as amended, between each Fund, the Funds’ custodian, and BNP. As of October 31, 2016, the Pledge Agreement was assigned from BNP to BNP Paribas Prime Brokerage International, Ltd. Per the Pledge Agreement, borrowings under the Agreement are secured by assets of each Fund that are held by the Fund’s custodian in a separate account (the “pledged collateral”). On January 31, 2022, the pledged collateral was valued at $108,775,721, $250,352,659 and $465,756,309 for the Clough Global Dividend and Income Fund, Clough Global Equity Fund and Clough Global Opportunities Fund, respectively. Each Fund may, with 30 days notice, reduce the Maximum Commitment Financing (Initial Limit amount plus the increased borrowing amount in excess of the Initial Limit) to a lesser amount if drawing on the full amount would result in a violation of the applicable asset coverage requirement of Section 18 of the 1940 Act. Interest is charged at the three month LIBOR (London Inter-bank Offered Rate) plus 0.70% on the amount borrowed and 0.65% on the undrawn balance. Each Fund also pays a one-time arrangement fee of 0.25% on (i) the initial Limit and (ii) any increased borrowing amount in the excess of the initial Limit, paid in monthly installments for the six months immediately following the date on which borrowings were drawn by the Fund.

The Maximum Commitment Financing allowed under the Agreement is $63,303,213, $139,500,000 and $257,000,000 for the Clough Global Dividend and Income Fund, Clough Global Equity Fund and the Clough Global Opportunities Fund, respectively. For the period ended January 31, 2022, the average borrowings outstanding for Clough Global Dividend and Income Fund, Clough Global Equity Fund and Clough Global Opportunities Fund under the agreement were $63,223,336, $139,153,236 and $255,523,831, respectively, and the average interest rate for the borrowings was 0.90%. As of January 31, 2022, the outstanding borrowings for Clough Global Dividend and Income Fund, Clough Global Equity Fund and Clough Global Opportunities Fund were $63,303,213, $139,500,000 and $257,000,000, respectively. The interest rate applicable to the borrowings of Clough Global Dividend and Income Fund, Clough Global Equity Fund and Clough Global Opportunities Fund on January 31, 2022, was 1.02%.

The Lending Agreement is a separate side-agreement between each Fund and BNP pursuant to which BNP may borrow a portion of the pledged collateral (the “Lent Securities”) in an amount not to exceed the outstanding borrowings owed by a Fund to BNP under the Agreement. The Lending Agreement is intended to permit each Fund to significantly reduce the cost of its borrowings under the Agreement. BNP has the ability to re- register the Lent Securities in its own name or in another name other than the Fund to pledge, re-pledge, sell, lend or otherwise transfer or use the collateral with all attendant rights of ownership. (It is each Fund’s understanding that BNP will perform due diligence to determine the creditworthiness of any party that borrows Lent Securities from BNP.) Each Fund may designate any security within the pledged collateral as ineligible to be a Lent Security, provided there are eligible securities within the pledged collateral in an amount equal to the outstanding borrowing owed by a Fund. During the period in which the Lent Securities are outstanding, BNP must remit payment to each Fund equal to the amount of all dividends, interest or other distributions earned or made by the Lent Securities.

Under the terms of the Lending Agreement, the Lent Securities are marked to market daily, and if the value of the Lent Securities exceeds the value of the then-outstanding borrowings owed by a Fund to BNP under the Agreement (the “Current Borrowings”), BNP must, on that day, either (1) return Lent Securities to each Fund’s custodian in an amount sufficient to cause the value of the outstanding Lent Securities to equal the Current Borrowings; or (2) post cash collateral with each Fund’s custodian equal to the difference between the value of the Lent Securities and the value of the Current Borrowings. If BNP fails to perform either of these actions as required, each Fund will recall securities, as discussed below, in an amount sufficient to cause the value of the outstanding Lent Securities to equal the Current Borrowings. Each Fund can recall any of the Lent Securities and BNP shall, to the extent commercially possible, return such security or equivalent security to each Fund’s custodian no later than three business days after such request. If a Fund recalls a Lent Security pursuant to the Lending Agreement, and BNP fails to return the Lent Securities or equivalent securities in a timely fashion, BNP shall remain liable for the ultimate delivery to each Fund’s custodian of such Lent Securities, or equivalent securities, and for any buy-in costs that the executing broker for the sales transaction may impose with respect to the failure to deliver. Should the borrower of the securities fail financially, the Funds have the right to reduce the outstanding amount of the Current Borrowings against which the pledged collateral has been secured. Although risk is mitigated by the collateral, the Funds could experience a delay in recovering their securities and possible loss of income or value if the borrower fails to return the borrowed securities. Under the terms of the Lending Agreement, each Fund shall have the right to apply and set-off an amount equal to one hundred percent (100%) of the then current fair value of such Lent Securities against the Current Borrowings. As of January 31, 2022, the value of the Lent Securities for Clough Global Dividend and Income Fund, Clough Global Equity Fund and Clough Global Opportunities Fund were $60,097,893, $126,617,537 and $246,567,340, respectively.

The Board has approved each Agreement and the Lending Agreement. No violations of the Agreement or the Lending Agreement have occurred during the period ended January 31, 2022.